Company Overview: ONCOSEC

Industry News

11 May

OncoSec to Host Third Quarter Financial Conference Call on June 1, 2017

SAN DIEGO, May 11, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that the Company will host its fiscal third quarter 2017 financial results conference call on Thursday, June 1 at 1:15 PM PT/4:15 PM ET. To access the audio...

Read more

10 May

OncoSec Announces Clinical Collaboration with Merck to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Metastatic Melanoma

SAN DIEGO, May 10, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has entered a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada) to evaluate the combination of OncoSec’s ImmuoPulse® IL-12 with Merck’s anti-PD-1...

Read more

2 May

OncoSec to Present at Biomarkers & Immuno-Oncology World Congress 2017

SAN DIEGO, May 2, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that Robert H. Pierce, MD, OncoSec Chief Scientific Strategist, will speak at the Biomarkers & Immuno-Oncology World Congress, taking place May 2-4, 2017, in Philadelphia, PA. Details of the...

Read more

3 Apr

OncoSec Presents Preclinical Data Demonstrating Improved Systemic Anti-Tumor Response Following Modifications to IL-12 Gene Delivery Therapy at AACR Annual Meeting

SAN DIEGO, April 3, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented a poster titled “Intratumoral Delivery of a P2A-linked Bicistronic IL-12 Construct Leads to High Intratumoral Expression and Systemic Anti-tumor Response” (Abstract ID # 1614) at the American Association of...

Read more

28 Mar

OncoSec to Present Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2017

SAN DIEGO, March 28, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present preclinical results from recent studies describing the latest developments of its gene delivery platform, at a poster session at the upcoming American Association of Cancer Research (AACR) Annual Meeting,...

Read more

14 Mar

OncoSec Announces First Technology Access Program Agreement with Inhibrx

SAN DIEGO, March 14, 2017  /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that they have entered into a Technology Access Program (TAP) agreement with Inhibrx, LP, a privately held biotherapeutic company. Under the agreement, Inhibrx will use OncoSec’s proprietary gene...

Read more

2 Mar

OncoSec to Host Second Quarter Financial Conference Call on March 16, 2017

SAN DIEGO, March 2, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that the Company will host its fiscal second quarter 2017 financial results conference call on Thursday, March 16 at 1:15 PM PST/4:15 PM EST. To access the audio broadcast,...

Read more

27 Feb

OncoSec Granted FDA Fast Track Designation for ImmunoPulse® IL-12 for the Treatment of Metastatic Melanoma Following Progression on Pembrolizumab or Nivolumab

SAN DIEGO, Feb. 27, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its ImmunoPulse® IL-12, a potentially first-in-class, Intratumoral anti-cancer gene therapy that expresses interleukin-12 (IL-12) for the treatment of metastatic...

Read more

24 Feb

OncoSec to Host KOL Event Focused on New ASCO-SITC Melanoma Data and Clinical Strategy on Tuesday, February 28 in New York City

SAN DIEGO, Feb. 24, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will host a Key Opinion Leader event to highlight new clinical data that will be featured as an oral and poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and the...

Read more

23 Feb

OncoSec Announces Positive Phase II Data Demonstrating Company’s ImmunoPulse® IL-12 in Combination with Pembrolizumab Increased Response Rates in Anti-PD-1 Non-Responder Melanoma Patients

SAN DIEGO, Feb. 23, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today reported new positive clinical data from a Phase II Investigator Sponsored Trial assessing the combination of OncoSec’s investigational intratumoral therapy, ImmunoPulse® IL-12, and the approved anti-PD- 1 therapy (pembrolizumab), in...

Read more

Page 1 of 212

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address